Zobrazeno 1 - 1
of 1
pro vyhledávání: '"James S Dingman"'
Publikováno v:
Journal of Pharmacy Practice. 36:468-471
The growing use of oral factor Xa (FXa) inhibitors in patients with chronic kidney disease (CKD), particularly the recent increased use of apixaban in patients with end-stage renal disease (ESRD), has created a new dilemma in the already controversia